DUBLIN, Ireland--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of the two-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback